Tech Company Financing Transactions

Arsanis Funding Round

Bill & Melinda Gates Foundation, Alexandria Venture Investments and EMBL Ventures participated in a $45.5 million Series D capital raise for Arsanis. The financing round was announced on 4/27/2017.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

890 Winter St. 230
Waltham, MA 02451
USA

Phone

(781) 819-5704

Website

www.arsanis.com

Email Address

Not Recorded

Overview

Arsanis (NASDAQ: ASNS) is a biosciences company developing infectious disease treatments based on bacterial protein and carbohydrate antigens.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

René Russo

        

Chief Medical Officer

Chris Stevens

        

Chief Operating Officer

Michael Gray

        

Chief Scientific Officer

Eszter Magy

        

VP - Bus. Development

David Mantus

        

Browse more venture capital transactions:

Prev: 4/27/2017: RedShelf venture capital transaction
Next: 4/27/2017: ChromaCode venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary